Smart Cell Therapies for Solid Cancers Ready to Move Toward Clinical Trials | UC San Francisco
As CAR-T advances into solid tumors, glioblastoma emerges as area of opportunity
Immunotherapy for Medulloblastoma: Current Perspectives | ITT
Frontiers | Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future | Immunology
Clinical trials of the use of CAR T cells for the treatment of... | Download Table
Frontiers | CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma | Neuroscience
Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight | Journal of Translational Medicine | Full Text
Clinical development of CAR T cell therapy in China: 2020 update | Cellular & Molecular Immunology
CAR-T in solid tumors: Blazing a new trail through the brambles - ScienceDirect
Newly Diagnosed Glioblastoma: A Review on Clinical Management
New approaches to immunotherapy for glioblastoma - Mayo Clinic
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | NEJM
TCR discovery - Current and future directions in CAR-T and TCR-T
Our Pipeline – Chimeric Therapeutics
Cancers | Free Full-Text | Advances in Immunotherapy for Adult Glioblastoma | HTML
Clinical trials of CAR-T cells with fourth-generation CARs in China | Download Table
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme - Marei - 2021 - Cancer Medicine - Wiley Online Library
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials - Lung Cancer
Immunotherapy for glioma: Current management and future application - ScienceDirect
Chimeric antigen receptor T-cells for glioblastoma: The journey ahead Joseph SK, Ahmed NM, Hegde M - Glioma
GD2-CAR T cell therapy shows promise against deadly pediatric cancer in early clinical trial
Frontiers | CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma | Neuroscience
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | NEJM
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany | Gene Therapy
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | NEJM
